Navegar

Colección

Datos Estadísticas

Artículo

Martinez, L.A.; Yang, J.; Vazquez, E.S.; Rodriguez-Vargas, M.D.C.; Olive, M.; Hsieh, J.-T.; Logothetis, C.J.; Navone, N.M. "p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells" (2002) Carcinogenesis. 23(8):1289-1296
Estamos trabajando para incorporar este artículo al repositorio
Consulte el artículo en la página del editor
Consulte la política de Acceso Abierto del editor

Abstract:

Current therapy for advanced prostate cancer is largely based on androgen deprivation and is mostly palliative because all patients eventually relapse with androgen-independent disease. Doxorubicin (Dx), an anthracycline used commonly as a chemotherapeutic agent in relapsed prostate cancer, is a strong inducer of p53 expression and p21CIP1/WAF1 (p21) transactivation. Previous reports suggest that p21 may have a role in the modulation to chemotherapy-induced apoptosis, prostate cancer progression and androgen regulation. In order to investigate if p21 has a pro-survival role in the response of prostate cancer cells to cellular stress, we exposed two androgen-regulated human prostate cancer cell lines (MDA PCa 2b and LNCaP) to Dx and growth factor withdrawal. We then studied expression of p53 and p21, cell-cycle kinetics and apoptosis. We have found that p53 protein accumulated in a dose-and time-dependent manner after Dx treatment, while p21 expression increased over time with low but decreased with high Dx doses. Apoptosis occurred in parallel with p21 down-modulation. Dx treatment of p53 knockout cells demonstrated that p21 induction was strictly p53 dependent. Reduction of p21 levels in prostate cancer cells with an antisense p21 adenovirus resulted in sensitization to Dx and accelerated onset of apoptosis in response to growth factor withdrawal. The evidence presented here also suggests that caspase activation mediates the apoptosis in this system and supports that p21 may modulate the threshold of apoptosis in prostate cancer. These observations may thus provide implications onto the integration of chemotherapy and androgen ablation.

Registro:

Documento: Artículo
Título:p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells
Autor:Martinez, L.A.; Yang, J.; Vazquez, E.S.; Rodriguez-Vargas, M.D.C.; Olive, M.; Hsieh, J.-T.; Logothetis, C.J.; Navone, N.M.
Filiación:Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, United States
Department of Biological Chemistry, Facultad de Ciencias Exactas Y Naturales, University of Buenos Aires, Buenos Aires, Argentina
University of Texas Southwestern Medical Center, Dallas, TX 77030, United States
Palabras clave:androgen; anthracycline derivative; antineoplastic agent; antisense oligonucleotide; caspase; DNA; doxorubicin; growth factor; protein p21; protein p53; virus protein; Adenovirus; advanced cancer; apoptosis; article; cancer cell culture; cancer chemotherapy; cancer growth; cancer recurrence; cancer survival; cell cycle; cell kinetics; concentration response; controlled study; DNA damage; down regulation; drug sensitization; enzyme activation; hormonal regulation; hormone inhibition; human; human cell; knockout gene; nonhuman; oxidative stress; palliative therapy; priority journal; prostate cancer; protein expression; protein function; protein induction; regulatory mechanism; transactivation
Año:2002
Volumen:23
Número:8
Página de inicio:1289
Página de fin:1296
DOI: http://dx.doi.org/10.1093/carcin/23.8.1289
Título revista:Carcinogenesis
Título revista abreviado:Carcinogenesis
ISSN:01433334
CODEN:CRNGD
CAS:caspase, 186322-81-6; DNA, 9007-49-2; doxorubicin, 23214-92-8, 25316-40-9; protein p21, 85306-28-1
Registro:https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_01433334_v23_n8_p1289_Martinez

Referencias:

  • Gittes, R.F., Carcinoma of the prostate (1991) N. Engl. J. Med, 324, pp. 236-245
  • Catalona, W.J., Management of cancer of the prostate (1994) N. Engl. J. Med, 331, pp. 996-1004
  • Ellerhorst, J.A., Tu, S.M., Amato, R.J., Finn, L., Millikan, R.E., Pagliaro, L.C., Jackson, A., Logothetis, C.J., Phase II trial of alternating weekly chemotherapy for patients with hormone-refractory adenocarcinoma of the prostate (1997) Clin. Cancer Res, 3, pp. 2371-2376
  • Tu, S.M., Pagliaro, L.C., Banks, M.E., Amato, R.J., Millikan, R.E., Bugazia, N.A., Madden, T., Logothetis, C.J., Phase I study of suramine combined with doxorubicin in the treatment of androgen-independent prostate cancer (1998) Clin. Cancer Res, 4, pp. 1193-1201
  • Culine, S., Kattan, J., Zanetta, S., Theodore, C., Fizazi, K., Droz, J.P., Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer (1998) Am. J. Clin. Oncol, 21, pp. 470-474
  • Ko, L., Prives, C., p53: Puzzle and paradigm (1996) Genes Dev, 10, pp. 1054-1072
  • Navone, N.M., Troncoso, P., Pisters, L.L., Goodrow, T.L., Palmer, L.P., Nichols, W.W., von Eschenbach, A.C., Conti, C.J., p53 protein accumulation and gene mutation in the progression of human prostate carcinoma (1993) J. Natl Cancer Inst, 85, pp. 1657-1669
  • Navone, N.M., LaBate, M.E., Troncoso, P., Pisters, L.L., Conti, C.J., von Eschenbach, A.C., Logothetis, C.J., p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential (1999) J. Urol, 161, pp. 304-308
  • Li, R., Waga, S., Hannon, G.J., Beach, D., Stillman, B., Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair (1994) Nature, 371, pp. 534-537
  • Li, R., Hannon, G.J., Beach, D., Stillman, B., Subcellular distribution of p21 and PCNA in normal and repair-deficient cells following DNA damage (1996) Curr. Biol, 6, pp. 189-199
  • Waldman, T., Zhang, Y., Dillehay, L., Yu, J., Kinzler, K., Vogelstein, B., Williams, J., Cell-cycle arrest versus cell death in cancer therapy (1997) Nat. Med, 3, pp. 1034-1036
  • Gorospe, M., Cirielli, C., Wang, X., Seth, P., Capogrossi, M.C., Holbrook, N.J., p21 (Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells (1997) Oncogene, 14, pp. 929-935
  • Poluha, W., Poluha, D.K., Chang, B., Crosbie, N.E., Schonhoff, C.M., Kilpatrick, D.L., Ross, A.H., The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells (1996) Mol. Cell. Biol, 16, pp. 1335-1341
  • Gorospe, M., Wang, X., Guyton, K.Z., Holbrook, N.J., Protective role of p21 (Waf1/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells (1996) Mol. Cell. Biol, 16, pp. 6654-6660
  • Yu, D., Jing, T., Liu, B., Yao, J., Tan, M., McDonnell, T.J., Hung, M.C., Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase (1998) Mol. Cell, 2, pp. 581-591
  • Gervais, J., Seth, P., Zhang, H., Cleavage of CDK-inhibitor p21-CIP1/WAF1 by caspases is an early event during DNA damage-induced apoptosis (1998) J. Biol. Chem, 273, pp. 19207-19212
  • Levkau, B., Koyama, H., Raines, E.W., Clurman, B.E., Herren, B., Orth, K., Roberts, J.M., Ross, R., Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: Role of a caspase cascade (1998) Mol. Cell, 1, pp. 553-563
  • Aaltomaa, S., Lipponen, P., Eskelinen, M., Ala-Opas, M., Kosma, V.M., Prognostic value and expression of p21 (waf1/cip1) protein in prostate cancer (1999) Prostate, 39, pp. 8-15
  • Sarkar, F.H., Li, Y., Sakr, W.A., Grignon, D.J., Madan, S.S., Wood, D.P., Adsay, V., Relationship of p21 (WAF1) expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (PCa) (1999) Prostate, 40, pp. 256-260
  • Baretton, G.B., Klenk, U., Diebold, J., Schmeller, N., Lohrs, U., Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: Prognostic significance of p21/WAF1/CIP1 expression (1999) Br. J. Cancer, 80, pp. 546-555
  • Lancombe, L., Maillete, A., Meyer, F., Veilleux, C., Moore, L., Fradet, Y., Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy (2001) Int. J. Cancer, 95, pp. 135-139
  • Fizazi, K., Martinez, L.A., Sikes, C.R., The association of p21 (WAF-1/CIP1) with progression to androgen-independent prostate cancer (2002) Clin. Cancer Res, 8, pp. 775-781
  • Horoszewicz, J.S., Leong, S.S., Kawinski, E., Karr, J.P., Rosenthal, H., Chu, T.M., Mirand, E.A., Murphy, G.P., LNCaP model of human prostatic carcinoma (1983) Cancer Res, 43, pp. 1809-1818
  • Isaacs, W.B., Carter, B.S., Ewing, C.M., Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles (1991) Cancer Res, 51, pp. 4716-4720
  • Papandreou, C.N., Bogenrieder, T., Scher, H.I., Albino, A.P., Nanus, D.M., Expression and sequence analysis of the SDI1/WAF1/CIP1/p21 tumor suppressor gene in prostate cancer cell lines (1996) Int. J. Oncol, 8, pp. 1237-1241
  • Navone, N.M., Olive, M., Ozen, M., Establishment of two human prostate cancer cell lines derived from a single bone metastasis (1997) Clin. Cancer Res, 3, pp. 2493-2500
  • Navone, N.M., Rodriquez-Vargas, M.C., Benedict, W.F., Troncoso, P., McDonnell, T.J., Zhou, J.H., Luthra, R., Logothetis, C.J., TabBO: A model reflecting common molecular features of androgen-independent prostate cancer (2000) Clin. Cancer Res, 6, pp. 1190-1197
  • Beham, A.W., Sarkiss, M., Brisbay, S., Tu, S.M., von Eschenbach, A.C., McDonnell, T.J., Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo (1998) Int. J. Mol. Med, 1, pp. 953-959
  • Keiss, T.D., Slebos, R.J., Nelson, W.G., Kastan, M.B., Plunkett, B.S., Han, S.M., Lorincz, A.T., Cho, K.R., Human papillomavirus 16 E6 expression disrupts the p53 mediated cellular response to DNA damage (1993) Proc. Natl. Acad. Sci. USA, 90, pp. 988-992
  • Sambrook, J., Fritsch, E.F., Maniatis, T., (1989) Molecular Cloning: A Laboratory Manual, , 2nd Edn, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
  • Ruan, S., Okcu, M.F., Pong, R.C., Andreeff, M., Levin, V., Hsieh, J.T., Zhang, W., Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis (2-chloroethyl)-1-nitrosourea and cisplatin (1999) Clin. Cancer Res, 5, pp. 197-202
  • Song, Q., Lees-Miller, S.P., Kumar, S., DNA-dependent protein kinase catalytic subunit: A target for an ICE-like protease in apoptosis (1996) EMBO J, 15, pp. 3238-3246
  • Steller, H., Mechanisms and genes of cellular suicide (1995) Science, 267, pp. 1445-1449
  • Alnemri, E.S., Livingston, D.J., Nicholson, D.W., Salvesen, G., Thornberry, N.A., Wong, W.W., Yuan, J., Human ICE/CED-3 protease nomenclature (1996) Cell, 87, p. 171
  • Wood, D.E., Newcomb, E.W., Caspase-dependent activation of calpain during drug-induced apoptosis (1999) J. Biol. Chem, 274, pp. 8309-8315
  • Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J.P., Requirement for p53 and p21 to sustain G2 arrest after DNA damage (1998) Science, 282, pp. 1497-1501
  • McDonnell, T.J., Meyn, R.E., Robertson, L.E., Implications of apoptotic cell death regulation in cancer therapy (1995) Semin. Cancer Biol, 6, pp. 53-60
  • Bissonnette, N., Hunting, D.J., p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage (1998) Oncogene, 16, pp. 3461-3469
  • Craft, N., Sawyers, C.L., Mechanistic concepts in androgen-dependence of prostate cancer (1999) Cancer Metastasis Rev, 17, pp. 421-427
  • Lu, S., Liu, M., Epner, D.E., Tsai, S.Y., Tsai, M.-J., Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter (1999) Mol. Endocrinol, 13, pp. 376-384
  • Lu, S., Jenster, G., Epner, D.E., Androgen induction of cyclin-dependent kinase inhibitor p21 gene: Role of androgen receptor and transcription factor Sp1 complex (2001) Mol. Endocrinol, 14, pp. 753-760

Citas:

---------- APA ----------
Martinez, L.A., Yang, J., Vazquez, E.S., Rodriguez-Vargas, M.D.C., Olive, M., Hsieh, J.-T., Logothetis, C.J.,..., Navone, N.M. (2002) . p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis, 23(8), 1289-1296.
http://dx.doi.org/10.1093/carcin/23.8.1289
---------- CHICAGO ----------
Martinez, L.A., Yang, J., Vazquez, E.S., Rodriguez-Vargas, M.D.C., Olive, M., Hsieh, J.-T., et al. "p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells" . Carcinogenesis 23, no. 8 (2002) : 1289-1296.
http://dx.doi.org/10.1093/carcin/23.8.1289
---------- MLA ----------
Martinez, L.A., Yang, J., Vazquez, E.S., Rodriguez-Vargas, M.D.C., Olive, M., Hsieh, J.-T., et al. "p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells" . Carcinogenesis, vol. 23, no. 8, 2002, pp. 1289-1296.
http://dx.doi.org/10.1093/carcin/23.8.1289
---------- VANCOUVER ----------
Martinez, L.A., Yang, J., Vazquez, E.S., Rodriguez-Vargas, M.D.C., Olive, M., Hsieh, J.-T., et al. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis. 2002;23(8):1289-1296.
http://dx.doi.org/10.1093/carcin/23.8.1289